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VEGF compared with normal subjects, which is in contrastDecreased urinary excretion of vascular endothelial growth
with other proteinuric diseases. Moreover, decreasing clinicalfactor in idiopathic membranous glomerulonephritis.
activity (proteinuria) is accompanied by increasing VEGF ex-Background. Membranous glomerulonephritis (MGN) has,
cretion. Urinary VEGF may serve as an indicator of activityfor unknown reasons, an unpredictable and highly variable
of MGN.clinical course. Vascular endothelial growth factor (VEGF)
enhances endothelial cell proliferation, angiogenesis, microvas-
cular permeability, and monocyte chemotaxis, and it activates
proteinases. In normal kidneys, it is predominantly expressed Membranous glomerulonephritis (MGN), a prototypeby glomerular podocytes, where its physiological function and
of an immune-mediated glomerular disease, is character-role in development of renal diseases are obscure. This study
ized by abundant, nonselective proteinuria and highlywas designed to evaluate the urinary excretion of VEGF in
MGN compared with several other glomerular disease and to individual course and prognosis [1]. The antigen(s) caus-
asses its relationships to the clinical activity of MGN. ing human MGN is unknown. However, in Heymann
Methods. Urinary VEGF was studied during renal biopsy nephritis representing the experimental model of theusing a sandwich enzyme immunoassay from 30 patients with
disease, antibodies are directed against the megalinidiopathic MGN, 8 with minimal change glomerulonephritis,
(gp330) receptor-associated protein complexes in the10 with focal segmental glomerulosclerosis (FSGS), 8 with nec-
rotizing glomerulonephritis associated with systemic vasculitis, chlathrin-coated pits of the podocytes [2]. In the initial
and 12 with diabetic nephropathy. In addition, 33 healthy con- phases of the disease, the immune deposits are formed
trols were examined. Fifteen patients with MGN were re-evalu- beneath the podocytic foot processes and are later incor-ated 12 months later, and the evolution of proteinuria was
porated into the glomerular basement membrane [3].compared with changes in urinary VEGF excretion.
The immune process leads to generation of terminalResults. In healthy control subjects, urinary VEGF excretion
was 68 6 10 (95% CI, 49 to 88) ng/mmol creatinine (UCr). In complement complexes (C5a-9, membrane attack com-
MGN, the excretion was decreased to 16 6 3 (CI, 10 to 23) plex), which are essential for the development of protein-
ng/mmol crea (P , 0.0001, ANOVA), whereas in minimal
uria [4]. These complexes are capable of inducing thechange glomerulonephritis and diabetic nephropathy, it was
release of cytokines, oxidants, and proteinases, whichunchanged [55 6 14 (CI, 24 to 86) and 101 6 25 (CI, 45 to
156) ng/mmol UCr, respectively, P 5 NS]. In vasculitis and may be responsible for the altered permeability of the
FSGS patients, the excretion was higher than normal [184 6 glomerular capillary wall [5, 6].
68 (CI, 24 to 344), P 5 0.01, and 160 6 29 (CI 95 to 226), Progression of MGN is linked to the duration and
P 5 0.002 ng/mmol UCr, respectively]. The excretion did not degree of proteinuria [7, 8]. On the other hand, protein-correlate with serum VEGF, renal function, or proteinuria.
uria may resolve spontaneously [9] or as a result of immu-In the follow-up of 15 patients, improving MGN (decreasing
proteinuria) was associated with increasing VEGF excretion, nomodulating therapy [10, 11]. Factors regulating pro-
while persistent disease (no change or increase of proteinuria) tein excretion and the evolution of MGN are unknown.
was associated with constantly low urinary VEGF excretion. Vascular endothelial growth factor (VEGF; vascularThe change in urinary protein excretion over one year corre-
permeability factor) is a potent mitogen that enhanceslated inversely with the change in urinary VEGF (r 5 20.57,
the proliferation of vascular endothelial cells, angiogen-P 5 0.026).
Conclusions. MGN is associated with decreased urinary esis, and microvascular permeability [12, 13]. At least
four VEGF isoforms have been found, and they interact
with specific tyrosine kinase receptors Flt-1, Flt-4, andKey words: growth factors, glomerulonephritis, proteinuria, immune
process, sandwich enzyme immunoassay, vascular permeability. KDR/Flk-1 on endothelial cells [14, 15]. In normal kid-
neys, VEGF is expressed in glomerular epithelial cellsReceived for publication June 17, 1999
and weakly in distal tubular and connecting duct cellsand in revised form October 22, 1999
Accepted for publication January 2, 2000 [16, 17], as well as in the juxtaglomerular areas [18].
Also, human mesangial cells and peripheral blood mono-Ó 2000 by the International Society of Nephrology
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nuclear cells are capable of producing this molecule Laboratory analyses
[19, 20]. Some recent studies have suggested that the Urinary and serum samples. Urinary examinations
expression of VEGF is abnormal in many glomerular were based of 24-hour collections throughout the study.
and renal vascular diseases, as well as in renal allograft These were obtained at the hospital prior to renal biopsy
rejection [17, 21]. However, its role in renal pathophysi- and (in 15 patients with MGN) 12 months later during
ology is at present unclear. outpatient visits. Aliquots of the 24-hour urine collection
To study the urinary excretion of VEGF in various were centrifuged at 3000 r.p.m. for 10 minutes, and the
glomerular diseases and normal subjects, we developed clear supernatants were stored (without protease inhibi-
a novel sandwich enzyme immunoassay and correlated tors) at 2708C. Venous blood samples were collected in
the excretion with several clinical parameters and plasma prechilled tubes and centrifuged within 30 minutes, and
levels of VEGF. We also investigated the relationships serum samples were stored at 2208C.
between changes in clinical activity of MGN and urinary VEGF assay. Urinary VEGF was determined using a
VEGF excretion. sandwich enzyme immunoassay in which polyclonal goat
antibodies to human VEGF (hVEGF; R&D Systems,
Minneapolis, MN, USA) were precoated (0.5 mg/well)METHODS
onto microtiter wells. Standards (recombinant hVEGF,Study subjects
5000 to 0 ng/L; Genzyme Diagnostics, Cambridge, MA,
Patients. The study population comprised 30 patients USA), and samples were introduced to the wells. The
with idiopathic MGN [22, 23]. There were 20 males and VEGF in standards and/or samples, first bound to the
10 females, and their mean age was 45 6 2.9 (mean 6 coated antibody, was then detected by polyclonal rabbit
SE, median 43, range from 25 to 75) years. The protein antibody to hVEGF (Genzyme Diagnostics), followed
excretion at the start of the study was 7.1 6 0.7 (median by alkaline phosphatase-conjugated goat antibody to
6.2, range from 2.2 to 15.6) g/24 h. The serum creatinine rabbit IgG (Boerhinger Mannheim Corp., Indianapolis,
concentration was 91 6 6.2 (median 81, range from 57
IN, USA). Unreacted components were removed by
to 185) mmol/L, and the 24-hour creatinine clearance
washings. A chromogen solution added to the wellswas 1.5 6 0.1 (median 1.5, range from 0.7 to 2.4) mL/
formed a colored end product that was proportional tosec/1.73 m2. Samples for the study were obtained at the
the amount of VEGF present in the samples. Serumtime of morphologic diagnosis of MGN.
VEGF was determined as mentioned previously in thisFifteen patients with the nephrotic syndrome (protein-
article by using tenfold diluted sera. Detection limit ofuria more than 3 g/24 h) were followed up for at least
the assay was 10 ng/L, and for statistical purposes, values12 months, and were studied both at diagnosis of MGN
below this were assigned as 10 ng/L.and one year later. Seven of the 15 patients had full (uri-
Precision of the VEGF assay. Intra-assay and in-nary protein excretion deceased to less than 0.5 g/24 h)
terassay variations were 4.7 and 5.1% for the VEGF ator partial (protein excretion decreased by more than
a concentration of 1.5 ng/L, respectively, and 6.3 and50% compared with the initial values) remission during
6.7% for the VEGF at the concentration of 0.3 ng/L,the follow-up. Three of the patients received immuno-
respectively.modulating treatment (pulse methyl prednisolone or cy-
Analytical recovery of VEGF. Analytical recoveriesclosporine). In eight patients, the abundant proteinuria
of added recombinant VEGF 0.1, 0.5, and 2.0 ng/L (initialeither persisted or increased during the follow-up. Two
VEGF content was 0.27 6 0.01 ng/L) to aliquots (10 each)of them were treated with immunomodulating drugs.
of pooled urine ranged from 80 to 100%. When addedControls. Twenty-four–hour urinary samples were
to urines from three patients with MGN, the analyticalobtained in 38 patients before the renal biopsy (where
recoveries of 0.5 ng/L VEGF ranged from 86 to 123%.the diagnosis was done). Eight had minimal change glo-
Storage stability of VEGF. The pH values of urinemerulonephritis [male to female ratio 3:5, mean age 48 6
were adjusted to 5.3, 7.0, and 9.0. VEGF was added to5.6 years, serum creatinine (SCr) 76 6 5 mmol/L]. Ten
a final concentration of 0.5 ng/L. Aliquots of each samplehad focal glomerulosclerosis (male to female ratio 5:6,
were stored at 2208C, 48C, and room temperature, andmean age 39 6 4.3 years, SCr 141 6 39 mmol/L). Eight
VEGF was analyzed after 1, 6, 13, and 20 days. Therehad necrotizing glomerulonephritis (male to female ratio
was no significant loss of VEGF immunoreactivity at4:4, mean age 59 6 4.7 years, SCr 308 6 78 mmol/L)
pHs 5.3 and 7.0 during the storage at any temperatureusually associated with systemic vasculitis, and 12 had
even for 20 days. At a pH of 9.0, there were 20 and 30%overt (macroproteinuric) diabetic nephropathy (male to
loss of immunoreactivity, respectively, during 6 and 20female ratio 10:2, mean age 54 6 3.6 years, SCr 173 6 16
days at 248C. At 2258C, the loss of immunoreactivitymmol/L). In addition, the samples were obtained in 33
was about 2% at pH 9.0 during 6 to 20 days of storage.normal subjects (male to female ratio 21:12, mean age
37 6 1.7 years) who were studied as outpatients. To compensate for alterations caused by varying uri-
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nary concentration, the excretion of VEGF was related
to concomitant urinary creatinine (UCr).
Other laboratory analyses. Urinary tumor necrosis
factor-a (TNF-a) was analyzed using a solid-phase, dou-
ble-antibody radioimmunoassay [24], and urinary trans-
forming growth factor-b1 (TGF-b1) by an enzyme immu-
noassay [25]. Immunoturbidimetry was used to measure
the concentrations of urinary albumin [26] and a1-micro-
globulin [27]. Renal function was assessed by serum cre-
atinine (normal values from 50 to 130 mmol/L) and (in
MGN patients) by 24-hour creatinine clearance (normal
values . 1.4 mL/sec/1.73 m2). Serum creatinine, albumin,
as well as the urinary total protein, albumin, and creati-
nine were measured using routine methods.
Statistical analysis
Values are expressed as mean 6 SEM. Also, median
values as well as 95% CI are shown where appropriate.
One-way analysis of variance (ANOVA) was employed
for repeated measurements, and comparisons between
the two groups were performed with the Mann–Whitney
U-test. The changes in proteinuria and urinary VEGF
excretion were analyzed using two-tailed Wilcoxon’s
signed rank test. Simple linear regression analyses were
used to study interrelationships between various param-
eters. The calculations were performed using GraphPad
Prisme (GraphPad Software, Inc., San Diego, CA, USA)
software. P values of less than 0.05 were considered
significant.
RESULTS
Urinary VEGF in patients and control subjects
The urinary VEGF excretion was 68 6 10 (median 46;
Fig. 1. Urinary vascular endothelial growth factor (VEGF) excretion95% CI, 49 to 88) ng/mmol UCr in normal control subjects in different glomerular diseases and healthy control subjects. Abbrevia-
(Fig. 1). Patients with MGN excreted 16 6 3 (median 12; tions are: MGN, membranous glomerulonephritis; MC, minimal change
glomerulonephritis; FSGS, focal segmental glomerulosclerosis; VAS,CI, 10 to 23) ng/mmol UCr, which was significantly less
vasculitis; DNP, diabetic nephropathy; Control, healthy controls. Thethan the normal subjects (P , 0.0001, ANOVA). The
lines indicate the mean values for each group.
excretion was 55 6 14 (median 56; CI, 24 to 86) ng/mmol
UCr in patients with minimal change nephropathy (P 5
NS compared with the normal subjects). In focal segmen-
tal glomerulosclerosis (FSGS), the excretion was ele- Urinary VEGF did not correlate with albumin excre-
tion (r 5 20.002, P 5 NS), urinary a1-microglobulin (r 5vated to 160 6 29 (median 154; CI, 95 to 226) ng/mmol
UCr (P 5 0.002), and in necrotizing glomerulonephritis, 0.03, P 5 NS), SCr (r 5 20.2, P 5 NS), or 24-hour
creatinine clearance (r 5 0.28, P 5 NS) in patients withthe urinary VEGF excretion of 184 6 68 (median 127;
CI, 24 to 344) ng/mmol UCr was also elevated compared MGN. There was no significant correlation to urinary
TGF-b1 (r 5 0.02, P 5 NS) or urinary TNF-a excretionwith the normal subjects (P 5 0.01). In diabetic nephrop-
athy, the urinary VEGF excretion was 101 6 25 (median (r 5 0.22, P 5 NS). Moreover serum VEGF concentra-
tions did not correlate with urinary VEGF (r 5 20.28,88; CI, 45 to 156) ng/mmol UCr (P 5 NS).
The median serum VEGF concentration was 80 (range P 5 NS) in patients with MGN or in any of the control
groups with various glomerular diseases (data not shown).from 5.0 to 14,800) ng/L in patients with MGN, 60 (5 to
1,100) ng/L in minimal change nephropathy, 288 (5 to
Clinical activity of MGN and urinary VEGF11,250) ng/L in FSGS, 120 (5 to 20,000) ng/L in necrotiz-
ing glomerulonephritis, and 260 (20 to 3,500) ng/L in Associations between changes in the clinical activity
of MGN (assessed by proteinuria) and urinary VEGFpatients with diabetic nephropathy (P 5 NS, ANOVA).
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Fig. 2. Patients with improving membranous
glomerulonephritis. Changes in urinary pro-
tein (A) and VEGF (B) excretion over one
year.
Fig. 3. Patients with persistent membranous
glomerulonephritis. Changes in urinary pro-
tein (A) and VEGF (B) excretion over one
year.
were studied in 15 patients presenting with the nephrotic their urinary protein excretion decreased by at least 50%
during the follow-up (improving MGN). In this group,syndrome. They were followed up for 12 (range, 10 to
14) months after the initial renal biopsy (that is, diagnosis proteinuria decreased from 8.2 6 1.6 to 2.0 6 0.7 g/24 h
(P 5 0.016), while the urinary VEGF excretion increasedof MGN). These patients were divided into two groups
according to the evolution of proteinuria (Figs. 2 and 3). from 6.6 6 1.3 to 36.2 6 8.4 ng/mmol UCr (P 5 0.016).
In eight patients (Fig. 3), the abundant urinary proteinSeven patients (Fig. 2) either entered remission or
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dependent on normal activity of VEGF, which may me-
diate communication between Bowman’s capsule and
capillary endothelial cells [31]. In normal fetal and adult
kidneys, the most intense VEGF production is found in
podocytes and collecting duct cells, and the mRNA for
its receptors is seen in glomerular endothelia and peritu-
bular capillaries [32]. Its physiological function in kid-
neys, as well as role in the pathogenesis of renal diseases,
is, however, unclear.
Certain features of VEGF suggest that it might be
involved in altered glomerular permeability and patho-
physiology. It is a highly potent inducer of vascular per-
meability. It affects the chemotaxis of monocytes and
activates proteases [13, 28]. In protein-overload nephro-
sis induced using bovine serum albumin, the glomerular
expression of mRNA of VEGF and its receptors corre-
lated with the severity of proteinuria [33], whereas the
Fig. 4. Correlation between the change in urinary protein excretion
expression was profoundly down-regulated in experi-(D proteinuria) and VEGF excretion (D urinary VEGF) during a one-
mental anti-glomerular basement membrane glomerulo-year follow-up (r 5 0.57; P , 0.026).
nephritis and puromycin aminonucleoside nephrosis
(abstract; Tang et al, J Am Soc Nephrol 6:855, 1995).
However, although the administration of VEGF to non-
excretion either persisted or increased (persistent MGN). nephritic rats led to a reversible fall in blood pressure,
In this group, proteinuria was 6.5 6 0.9 g/24 h initially it did not induce proteinuria or glomerular histologic
and 10.6 6 2.9 g/24 h at 12 months (P 5 NS). The urinary changes [34]. Likewise, VEGF did not affect glomerular
VEGF excretion was 10.7 6 1.6 ng/mmol UCr initially permeability for albumin in isolated perfused rat kid-
and 7.6 6 1.4 ng/mmol UCr at 12 months (P 5 NS). neys, but it enhanced the relaxation of renal vasculature
Figure 4 shows the combined data of the 15 patients. after norepinephrine infusion, an effect dependent on
There was a negative correlation between the change of nitric oxide [35]. In the experimental anti-Thy nephritis,
proteinuria during the follow-up and the change in uri- VEGF may participate the healing of the lesions [36].
nary VEGF excretion (r 5 20.57, P 5 0.026). Thus, as Some previous articles have focused on the expression
the activity of MGN decreased either spontaneously or of VEGF in human renal diseases. In the study of Gro¨ne,
as a result of therapy, the urinary VEGF excretion in- Simon, and Gro¨ne, VEGF mRNA and protein were ex-
creased and vice versa. pressed in proximal and distal tubular epithelia, particu-
larly in conditions showing acute vascular obstruction
such as acute vascular allograft rejection or necrotizingDISCUSSION
vasculitis [17]. Interestingly, in the present study, patients
In the present study, we examined 69 patients with a with necrotizing glomerulonephritis had elevated urinary
variety of glomerular diseases and 33 normal subjects. It VEGF excretion. This finding is in concord with a recent
appeared that the normal subjects had detectable urinary preliminary article in which elevated serum VEGF levels
VEGF excretion, and compared with them, the excretion were observed in pauci-immune (perinuclear antineutro-
was unchanged in diabetic nephropathy and minimal phil cytoplasmic antibody positive) rapidly progressive
change glomerulonephritis, but was elevated in patients glomerulonephritis [37]. The up-regulated expression
with FSGS and necrotizing glomerulonephritis. In con- (and urinary excretion) of VEGF in vasculitis may be
trast, MGN was associated with significantly decreased caused by hypoxia, which has previously been shown
urinary VEGF excretion, while decreasing clinical activ- to induce VEGF gene and protein as well as receptor
ity (proteinuria) was associated with increasing urinary expression [38, 39].
VEGF excretion toward the levels observed in the Shulman et al studied 47 patients with a variety of
healthy subjects. renal diseases using immunohistochemistry and in situ
Vascular endothelial growth factor has been suggested hybridization [21]. They observed that VEGF expression
to have an essential role in angiogenesis, and it is also was decreased or absent in sclerotic glomeruli, glomeruli
a central molecule in embryonic development, wound compressed by crescents, glomeruli with a marked hyper-
healing, and tumor growth [13, 28]. Its overexpression cellularity (systemic lupus erythematosus), and in areas
is observed in immunologic dermatologic diseases like occupied by matrix nodules (diabetic nephropathy).
More specifically, the three patients with MGN showedpsoriasis and pemphigoid [29, 30]. Glomerulogenesis is
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expression of VEGF in preserved glomeruli. In the con- nal fibrotic processes [25] or with a1-microglobulin, an
genital nephrotic syndrome of the Finnish type, no con- indicator of proximal tubular cell injury [27].
sistent changes in the production or expression of VEGF Since the early immunologic processes in MGN affect
or its receptor KDR were found in the study of Haltia glomerular podocytes, which in normal kidneys are the
et al [18]. Mesangial VEGF expression has been reported major site for production and expression of VEGF, it is
to be characteristic for early lesions of human mesangial possible that the podocyte injury results in their blunted
proliferative glomerulonephritis [20]. Webb et al studied capacity to secrete VEGF. As the clinical activity of
steroid-sensitive nephrotic syndrome in childhood [34]. the disease decreased either spontaneously or following
No alterations in serum concentration, peripheral blood immunomodulating therapy, a markedly increased uri-
mononuclear cell mRNA expression, or urinary excre- nary VEGF excretion was evident in our patients. This
tion of VEGF were found during relapses. Interestingly, may hypothetically be explained by at least partial recov-
it was recently suggested that urine from patients with ery of the podocyte injury in these patients. Further
benign prostatic hyperplasia and prostate cancer in- studies are warranted to show if the diminished urinary
creased capillary endothelial cell proliferation, while uri- VEGF excretion is specific for active MGN. Moreover,
nary VEGF excretion was increased in the former and serial determination of urinary VEGF may be more use-
decreased in the latter condition [40]. In contrast, urinary ful than single measurements in the assessment of the
VEGF (from morning mid stream specimens) was ele- activity of MGN.
vated and correlated with tumor recurrence rate in pa- In conclusion, we used an enzyme immunoassay to
tients with bladder cancer [41]. study urinary VEGF excretion in a variety of glomerular
The available data on VEGF in MGN are thus scant, diseases. The findings suggest for a decreased VEGF
and to our knowledge no previous studies have used excretion in clinically active MGN but not in the other
urinary assays of this molecule in various renal diseases. conditions studied. At follow-up, changes in protein ex-
The assay used may not necessarily measure the intact cretion correlated inversely with changes in VEGF ex-
functional VEGF molecule. Even if we, in part, are mea- cretion. Hence, in patients with partial of full clinical re-
suring nonfunctional VEGF or its degradation products, mission (assessed by proteinuria), the excretion increased.
the assay still revealed a clear difference between MGN Urinary VEGF may reflect the immunologic podocyte
and other diseases studied. The significance of the de- injury in MGN.
creased urinary VEGF excretion in our patients with
MGN is speculative. This phenomenon was not observed ACKNOWLEDGMENTS
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